D-(+)-(2-氯苯)甘氨酸 | 86303-23-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: D-(+)-(2-氯苯)甘氨酸
• 中文别名: N,N-双[3-(D-葡萄糖酰氨基)丙基]-3,12-二羟基胆甾烷-24-胺；脱氧BIGCHAP；(3a,5b,12a)-N,N-双[3-(D-葡萄糖酰氨基)丙基]-3,12-二羟基胆甾烷-24-胺；(3A,5B,12A)-N,N-双[3-(D-葡萄糖酰氨基)丙基]-3,12-二羟基胆甾烷-24-胺
• 英文名称: Deoxy-bigchap
• 英文别名: (2R,3S,4R,5R)-N-[3-[[(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]-[3-[[(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoyl]amino]propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide
• CAS: 86303-23-3
• 化学式: C₄₂H₇₅N₃O₁₅
• 分子量: 862.1
• InChiKey: OJSUWTDDXLCUFR-HGZMBBKESA-N

物化性质

• 熔点：
  89-91°C
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  60
• 可旋转键数：
  22
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  321
• 氢给体数：
  14
• 氢受体数：
  15

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 安全说明：
  S26,S36

文献信息

• PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS
  申请人：Philippe Michel

  公开号：US20100028280A1

  公开（公告）日：2010-02-04

  The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

  该发明涉及一种直发角蛋白纤维的拉直过程，包括：(i)将至少两种变性剂含有的拉直组合物涂抹到角蛋白纤维上的步骤，(ii)使用加热装置将角蛋白纤维的温度升高至110至250°C的步骤。
• Methods of treating diseases responsive to Induction of Apoptosis
  申请人：Kasibhatla Shailaja

  公开号：US20050004005A1

  公开（公告）日：2005-01-06

  The present invention pertains to a method of treating, preventing or ameliorating a disease responsive to induction of the caspase cascade in an animal, comprising administering to the animal a compound which binds specifically to a Tail Interacting Protein Related Apoptosis Inducing Protein (TIPRAIP). The present invention also relates to screening methods useful for drug discovery of apoptosis inducing compounds. In particular, the screening methodology relates to using TIPRAIP as a target for the discovery of apoptosis activators useful as anticancer agents. The screening methods of the present invention can employ homogenous or heterogenous binding assays using purified or partially purified TIPRAIP; or whole cell assays using cells with altered levels of TIPRAIP. The invention also contemplates use of 3-(4-azidophenyl)-5-(3-chloro-thiophen-2-yl)-[1,2,4]-oxadiazole or a substituted 3-aryl-5-aryl-[1,2,4]-oxadiazole which bind TIPRAIP and can accordingly be used to raise antibodies useful for drug discovery. Alternatively, labeled 3-(4-azidophenyl)-5-(3-chloro-thiophen-2-yl)-[1,2,4]-oxadiazole (or a labeled substituted 3-aryl-5-aryl-[1,2,4]-oxadiazole) is used for competitive binding assays for drug discovery. Such assays afford high throughput screening of chemical libraries for apoptosis activators.

  本发明涉及一种用于治疗、预防或改善对Caspase级联诱导敏感的动物疾病的方法，包括向动物投药一种与尾部相互作用蛋白相关凋亡诱导蛋白（TIPRAIP）特异结合的化合物。本发明还涉及有用于药物发现凋亡诱导化合物的筛选方法。特别是，筛选方法涉及使用TIPRAIP作为靶标，以发现作为抗癌剂有用的凋亡激活剂。本发明的筛选方法可以采用使用纯化或部分纯化的TIPRAIP的均相或异相结合分析；或使用具有改变TIPRAIP水平的细胞的全细胞分析。本发明还考虑使用3-（4-偶氮苯基）-5-（3-氯噻吩-2-基）-[1,2,4]-噁二唑或结合TIPRAIP的取代3-芳基-5-芳基-[1,2,4]-噁二唑，可用于制备有用于药物发现的抗体。或者，标记的3-（4-偶氮苯基）-5-（3-氯噻吩-2-基）-[1,2,4]-噁二唑（或标记的取代的3-芳基-5-芳基-[1,2,4]-噁二唑）可用于药物发现的竞争结合分析。这种分析为化学文库的高通量筛选提供了凋亡激活剂。
• Methods of treating diseases responsive to induction of Apoptosis and screening assays
  申请人：Kasibhatla Shailaja

  公开号：US20050004026A1

  公开（公告）日：2005-01-06

  The present invention pertains to a method of treating, preventing or ameliorating a disease responsive to induction of the caspase cascade in an animal, comprising administering to the animal a compound which binds specifically to one or more Apoptosis Inducing Proteins (AIPs). AIPs include Transferrin Receptor Related Apoptosis Inducing Proteins (TRRAIPs), Clathrin Heavy Chain Related Apoptosis Inducing Proteins (CHCRAIPs), IQ motif containing GTPase Activating Protein Related Apoptosis Inducing Proteins (IQGAPRAIPs), and Heat Shock Protein Related Apoptosis Inducing Proteins (HSPRAIPs). The present invention also relates to screening methods useful for drug discovery of apoptosis inducing compounds. In particular, the screening methodology relates to using AIPs as a target for the discovery of apoptosis activators useful as anticancer agents. The screening methods of the present invention can employ homogenous or heterogenous binding assays using purified or partially purified AIPs; or whole cell assays using cells with altered levels of one or more AIPs. The invention also contemplates use of gambogic acid or GA-related compounds which bind AIPs and can accordingly be used to raise antibodies useful for drug discovery. Alternatively, labeled GA is used for competitive binding assays for drug discovery. Such assays afford high throughput screening of chemical libraries for apoptosis activators.

  本发明涉及一种治疗、预防或改善动物中对caspase级联诱导敏感的疾病的方法，包括向动物中注射一种与一种或多种凋亡诱导蛋白（AIPs）特异结合的化合物。AIPs包括转铁蛋白受体相关凋亡诱导蛋白（TRRAIPs）、衣蛋白重链相关凋亡诱导蛋白（CHCRAIPs）、IQ基序含有GTP酶激活蛋白相关凋亡诱导蛋白（IQGAPRAIPs）和热休克蛋白相关凋亡诱导蛋白（HSPRAIPs）。本发明还涉及用于药物发现凋亡诱导化合物的筛选方法。特别地，筛选方法涉及使用AIPs作为发现凋亡激活剂用于抗癌药物的靶点。本发明的筛选方法可以使用纯化或部分纯化的AIPs进行同质或异质结合分析的细胞分析，或使用具有改变一种或多种AIPs水平的细胞进行整个细胞分析。本发明还考虑使用结合AIPs的苦参酸或GA相关化合物，可用于制备用于药物发现的抗体。或者，标记的GA可用于竞争性结合分析，用于药物发现。这种分析可用于高通量筛选化学库以寻找凋亡激活剂。
• Insulin standard solution
  申请人：TOA MEDICAL ELECTRONICS CO., LTD.

  公开号：EP0689052A2

  公开（公告）日：1995-12-27

  An insulin standard solution including an amide derivative of bile acid as a stabilizer having the formula (I): wherein A is a hydrogen atom or hydroxyl group, B has the formula : or and C is a hydrogen atom or a group having the formula :

  一种胰岛素标准溶液，包括作为稳定剂的胆汁酸酰胺衍生物，具有式 (I)： 其中 A 为氢原子或羟基，B 为式： 或 和 C 是氢原子或具有式：
• A method for measuring the concentration of protease inhibitors, kit for use in such a method and method for dissolving a sunstrate
  申请人：KABUSHIKI KAISHA KYOTO DAIICHI KAGAKU

  公开号：EP0814167A1

  公开（公告）日：1997-12-29

  This invention provides a method for measuring the concentration of urinary trypsin inhibitors which is excellent in precision and reproducibility, whose operation is simple, and in which a possibility of damaging a plastic cell is eliminated. The method for measuring the concentration of urinary trypsin inhibitors comprises mixing an urine sample, a protease solution containing trypsin, and a buffer solution, adding a substrate solution to the mixture to cause the enzyme reaction, and measuring the activity of the enzyme, wherein the buffer solution is prepared so that it contains at least 0.15µmol calcium per 1 µg of the trypsin but no more than 100µmol calcium per 1ml of the urine sample in the reaction mixture, and wherein the substrate solution is prepared by dissolving the substrate in an organic solvent and diluting the mixture solution with aqueous medium, wherein at least one of an amphoteric surfactant and a nonionic surfactant is added to at least one of the organic solvent and the aqueous medium.

  本发明提供了一种测量尿液中胰蛋白酶抑制剂浓度的方法，该方法精度高，重现性好，操作简单，而且消除了损坏塑料电池的可能性。测量尿液胰蛋白酶抑制物浓度的方法包括将尿液样品、含有胰蛋白酶的蛋白酶溶液和缓冲溶液混合，向混合物中加入底物溶液以引起酶反应，并测量酶的活性，其中缓冲溶液的配制使其至少含有 0.其中底物溶液的制备方法是将底物溶解在有机溶剂中并用水性介质稀释混合物溶液，其中两性表面活性剂和非离子表面活性剂中的至少一种添加到有机溶剂和水性介质中的至少一种中。